<p>
    Eight diagnostic tests or devices supported by the EDRN have been approved by the U.S. Food and Drug Administration for clinical use and
    <a href='clia-approved-tests'>18 EDRN developed biomarker tests</a>
    are available in Clinical Laboratory Improvement Amendments (CLIA) approved laboratories.  Details on the EDRN-supported biomarkers that received FDA approval are listed below.
</p>
<table class='listing biomarkerTable'
    summary='Eight different biomarkers or devices each listed with their purpose, year of approval and the EDRN prinicpal investigators and their industrial partners responsible.'>
    <thead>
        <tr>
            <th>Biomarker/Device</th>
            <th>Purpose</th>
            <th>Year of Approval</th>
            <th>EDRN Prinicpal Investigators<br/><em>Industrials Partners</em></th>
        </tr>
    </thead>
    <tbody>
        <tr>
            <td><strong>EsoCheck™</strong></td>
            <td>
                Allows patients to undergo a non-invasive five-minute office-based procedure to detect Barrett's
                Esophagus
            </td>
            <td>2019 FDA-cleared tool</td>
            <td>Sanford Markowitz, M.D.<br/><em>PAVmed</em></td>
        </tr>
        <tr>
            <td><strong>CancerSEEK</strong></td>
            <td>Detection of genetic mutations associated with pancreatic and ovarian cancer.</td>
            <td>2019 FDA break through device</td>
            <td>
                Ken Kinzler, Ph.D., Robert Schoen, M.D., Randall Brand, M.D., Peter Allen, M.D., and Samir Hanash, M.D.<br/>
                <em>Thrive Detection Corp.</em>
            </td>
        </tr>
        <tr>
            <td>
                <strong>Overa</strong>(5 analytes:
                <a href='@@dataDispatch?subjectURI=http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/20'>CA 125</a>,
                <a href='@@dataDispatch?subjectURI=http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/223'>apolipoprotein A-1</a>,
                <a href='@@dataDispatch?subjectURI=http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/73'>transferrin</a>,
                <a href='@@dataDispatch?subjectURI=http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/228'>follicle-stimulating hormone</a>,
                human epididymis protein 4)
            </td>
            <td>Prediction of ovarian cancer risk in women with adnexal mass.</td>
            <td>2016</td>
            <td>Zhen Zhang, Ph.D. and Daniel Chan, Ph.D.<br/><em>Vermillion</em></td>
        </tr>
        <tr>
            <td><strong>
                <a href='@@dataDispatch?subjectURI=http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/118'>%[-2]proPSA</a>
            </strong></td>
            <td>Reduce the number of unnecessary initial biopsies during prostate cancer screening.</td>
            <td>2012</td>
            <td>Daniel Chan, Ph.D.<br/><em>Beckman Coulter</em></td>
        </tr>
        <tr>
            <td><strong><a href='@@dataDispatch?subjectURI=http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/63'>PCA3</a> 
            (Prostate Cancer Antigen 3) RNA in urine</strong></td>
            <td>Determination of need for biopsy or repeat-biopsy in patients at risk for prostate cancer.</td>
            <td>2012</td>
            <td>John Wei, M.D.<br/><em>Gen-Probe</em></td>
        </tr>
        <tr>
            <td><strong>Risk of Ovarian Malignancy
            (<a href='@@dataDispatch?subjectURI=http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/966'>ROMA</a>)
            algorithm</strong></td>
            <td>Prediction of ovarian cancer risk in women with pelvic mass.</td>
            <td>2011</td>
            <td>Steve Skates, Ph.D.<br/><em>Fujirebio Diagnostics</em></td>
        </tr>
        <tr>
            <td><strong>
                <a href='@@dataDispatch?subjectURI=http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/19'>DCP</a> and
                <a href='@@dataDispatch?subjectURI=http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/37'>AFP-L3</a>; 
                a combined panel of biomarkers
            </strong></td>
            <td>Risk assessment for development of hepatocellular carcinoma.</td>
            <td>2011</td>
            <td>Jorge Marrero, M.D.<br/><em>Wako Diagnostics</em></td>
        </tr>
        <tr>
            <td>
                <strong>
                    <a href='@@dataDispatch?subjectURI=http://edrn.jpl.nasa.gov/bmdb/biomarkers/view/547'>
                        OVA1™
                    </a>
                </strong>
                (5 analytes: CA 125, prealbumin, apolipoprotein A-1, beta2 microglobulin, transferrin)
            </td>
            <td>Prediction of ovarian cancer risk in women with adnexal mass.</td>
            <td>2009</td>
            <td>Daniel Chan, Ph.D. and Zhen Zhang, Ph.D.<br/><em>Vermillion</em></td>
        </tr>
    </tbody>
</table>
